Ivosidenib, a selective IDH1 inhibitor, gained entry into the AML treatment toolbox after the publication of results from phase 1 study in which 125 R/R AML patients received 500 mg of ivosidenib once daily. The gene discussed is IDH1; the disease is acute myeloid leukemia.